Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | 0.00% | 0.00% |
Apr. 26 | Motion for Asset Sale Approved for Biocept, Inc. | CI |
Apr. 02 | Motion for Asset Sale Approved for Biocept, Inc. | CI |
Financials (USD)
Sales 2021 | 61.25M | Sales 2022 | 25.86M | Capitalization | 9.04M |
---|---|---|---|---|---|
Net income 2021 | -2M | Net income 2022 | -32M | EV / Sales 2021 | 0.73 x |
Net cash position 2021 | 16.19M | Net cash position 2022 | 788K | EV / Sales 2022 | 0.32 x |
P/E ratio 2021 |
-18.9
x | P/E ratio 2022 |
-0.28
x | Employees | 50 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 100% |
Latest transcript on Biocept, Inc.
1 day | -99.00% |
Managers | Title | Age | Since |
---|---|---|---|
Barbara Blouw
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Nathaniel Sweed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | 60 | 22-03-07 |
1st Jan change | Capi. | |
---|---|---|
0.00% | 2 | |
-1.29% | 12.64B | |
-0.47% | 8.46B | |
+22.61% | 5.27B | |
-2.03% | 4.49B | |
-53.56% | 3.11B | |
+19.30% | 2.87B | |
+33.07% | 2.31B | |
-8.42% | 2.23B | |
-3.55% | 1.89B |
- Stock Market
- Equities
- BIOCQ Stock